Search result for CELLTRION
EU approves Celltrion's COVID-19 antibody treatment
The European Union's drug agency has approved the COVID-19 antibody treatment by Celltrion Inc. This is a milestone for the South Korean pharmaceutical company as it will pave the way for the sale of the treatment in the region.
Highlights
• &nb...
S. KOREAN STOCKS END LOW ON THURSDAY; KOSPI FELL
Highlights –
- S. Korean stocks end low on Thursday; KOSPI fell.
- KOSPI fell 7.4 points, or 0.23 percent, to close at 3,174.07 points.
- Samsung Electronics stocks lost 0.49 percent to 81,700 won.
- SK hynix stocks closed unchange...
S. KOREAN STOCK END LOW OVER RISING VALUATION PRESSURE
Highlights –
- S. Korean stock end low over rising valuation pressure.
- The KOSPI fell 1.38 points, or 0.36 percent,.
- Samsung Electronics stocks lost 1.3 percent to 83,600 won.
- SK Hynix stocks fell 2.78 percent to 140,000 won....
CELLTRION WILL SUPPLY ITS COVID-19 TREATMENT WITHOUT PROFIT MARGIN IN S. KOREA
Highlights –
- Celltrion will supply its COVID-19 treatment without profit margin in S. Korea.
- Celltrion’s CT-P59 began to be supplied to local medical institutions on Wednesday.
- The company has also planned to supply the treatmen...
CELLTRION’S COVID-19 ANTIBODY TREATMENT CONFIRMED TO NEUTRALIZE VIRUS VARIANT
Highlights –
- Celltrion’s COVID-19 antibody treatment confirmed to neutralize virus variant.
- The company’s CT-P59, an anti-COVID-19 monoclonal antibody treatment neutralized the British virus variant.
- The company has also t...
S. KOREA APPROVES CELLTRION INC.’S COVID-19 ANTIBODY TREATMENT WITH CONDITIONS
Highlights –
- S. Korea approves Celltrion Inc.’s COVID-19 antibody treatment with conditions.
- The country’s drug safety agency has given conditional marketing authorization of CT-P59.
- Celltrion plans to conduct a global pha...
S. KOREAN STOCKS OVER FOREIGN AND INSTITUTIONAL BUYING CLOSED HIGH ON MONDAY
Highlights –
- S. Korean stocks over foreign and institutional buying closed high on Monday.
- KRX reported the KOSPI jumped 80.32 points, or. 2.7 percent.
- Samsung Electronics added 1.22 percent to 83,000 won.
- SK Hynix Inc. sto...
SOUTH KOREA’S OWN COVID-19 VACCINE TO BE DEVELOPED LATE NEXT YEAR
Highlights –
- South Korea’s own COVID-19 vaccine to be developed late next year.
- South Korean Prime Minister announced the same on Thursday.
- Whereas foreign vaccines are scheduled to be administered starting early next year. ...
S. KOREA GOVERNMENT TO INVEST $470 BILLION IN BIOTECHNOLOGY IN FISCAL 2021
Highlights –
- S. Korea government to invest $470 billion in biotechnology in fiscal 2021.
- The country’s Ministry of Science and ICT represents a 24.9% hike from 2020.
- Until 2030 the government plans to spend a total of 2.2 trilli...
SARTORIUS TO PLOUGH $100 MILLION IN SONGDO BIOCLUSTER
- Sartorius, a German life sciences company with 170 years of background history, announced Thursday it will pour funds to the tune of $100 million in South Korea’s bio cluster of Songdo in Incheon to build a manufacturing facility for biologics plant parts.
- Sartorius&rsquo...
SOUTH KOREAN PHARMAS JOIN NATION-FRAUGHT RACE TO DEVELOP COVID-19 VACCINE
- South Korean pharmaceutical companies have joined the rat race to develop vaccines and treatments for the novel coronavirus, and several of them have received the nod for clinical trials from the country's drug safety agency.
- Among the front-runners is Celltrion Inc.'s ...
CELLYTRION TO EXPAND COVID-19 TESTING PORTFOLIO
HIGHLIGHTS
- Collaborating with BBB, Celltrion is planning to launch POCT kit in July 2020.
- Celltrion wants to distribute a second test, a COVID-19 RDT kit via agreement with Humasis.
Celltrion Group wants to expand its diagnostic port...
CELLTRION TO TAKE 6 MONTHS TO START COVID-19 DRUG TRIALS
Highlights –
- Celltrion Chairman shared the group’s efforts on COVID-19 cure development
- Chairman took to YouTube live stream to inform the general public
- Celltrion has been collecting samples to narrow down the antibody drugs
CELLTRION’S YEAR-END PROFIT, BIOSIMILARS DEMAND AT THE OVERSEAS MARKET
Highlights –
- Pharmaceutical giant Celltrion makes operating profit
- Biosimilars in demand
- Company aims to add 46 more new drugs by 2022
South Korean pharmaceutical giant and leading drug maker Celltrion Inc. ha...
Korean biopharmaceuticals expands its global presence
Based on a report, local pharmaceutical companies in South Korea are shifting their gaze to overseas markets. Reports allege 209 pharmaceutical companies have extended their businesses in 2018, these include establishing plants or subsidiaries, the number increased four times from 2016. Sou...
Korea advances towards the Chinese market
Korean pharmacy and biopharma companies are considering the unavoidable: the progress to the Chinese market. Rendering to Korea Health Industry Development Institute, Friday, China was the second biggest market for pharmaceuticals after the US in 2018.
The Chinese pharmacy market was se...